financetom
Business
financetom
/
Business
/
US FDA approves J&J's ketamine-based therapy to treat depression
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA approves J&J's ketamine-based therapy to treat depression
Jan 21, 2025 5:40 AM

Jan 21 (Reuters) - The U.S. Food and Drug Administration

approved Johnson & Johnson's ( JNJ ) ketamine-based nasal spray

Spravato, to treat adults with major depressive disorder, the

company said on Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved